Molecular assessment of artemisinin resistance markers, polymorphisms in the K13 propeller, and a multidrug-resistance gene in the Eastern and Western Border Areas of Myanmar

Clinical Infectious Diseases

Volumn 60, Issue 8, 2015, Pages 1208-1215

  Nyunt, Myat Htut ^a,b   Hlaing, Thaung ^a   Oo, Htet Wai ^a   Tin Oo, Lu Lu Kyaw ^a   Phway, Hnin Phyu ^a   Wang, Bo ^b   Zaw, Ni Ni ^a   Han, Soe Soe ^a   Tun, Thurein ^a   San, Kyaw Kyaw ^a   Kyaw, Myat Phone ^a   Han, Eun Taek ^b  

^a Department of Medical Research ^*  (Myanmar)

^b Kangwon National University   (South Korea)

Author keywords

artemisinin resistance; K13 propeller; Myanmar; pfmrp1; Plasmodium falciparum

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; MOLECULAR MARKER; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; PROTOZOAL DNA; PROTOZOAL PROTEIN;

ADULT; ARTICLE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; K13 PROPELLER GENE; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; MICROBIAL GENE; MYANMAR; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM FALCIPARUM MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1 GENE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT; ADOLESCENT; CHEMISTRY; CHILD; DNA SEQUENCE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR GENETICS; PARASITOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; MYANMAR; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84926654867     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1160     Document Type: Article

References (30)

1. World Health Organization. World malaria report 2013. Geneva, Switzerland: WHO, 2013.
2. World Health Organization. Global report on antimalarial efficacy and drug resistance: 2000-2010. Geneva, Switzerland: WHO, 2010.
3. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. New Engl J Med 2008; 359:2619-20.
4. Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One 2013; 8:e57689.
5. World Health Organization. Emergency response to artemisinin resistance in the greater Mekong subregion. Regional framework for action 2013-2015. Geneva, Switzerland: WHO, 2013.
6. Sanchez C, Rotmann A, Stein W, Lanzer M. Polymorphisms within PfMDR1 alter the substrate specificity for antimalarial drugs in Plasmodium falciparum. Mol Microbiol 2008; 70:786-98.
7. Sidhu A, Uhlemann A, Valderramos S, Valderramos J, Krishna S, Fidock D. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 2006; 194:528-35.
8. Valderramos S, Valderramos J, Musset L, et al. Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog 2010; 6:e1000887.
9. Zakeri S, Hemati S, Pirahmadi S, Afsharpad M, Raeisi A, Djadid N. Molecular assessment of atpase6 mutations associated with artemisinin resistance among unexposed and exposed Plasmodium falciparum clinical isolates to artemisinin-based combination therapy. Malar J 2012; 11:373.
10. Phompradit P, Wisedpanichkij R, Muhamad P, Chaijaroenkul W, Na-Bangchang K. Molecular analysis of pfatp6 and pfmdr1 polymorphisms and their association with in vitro sensitivity in Plasmodium falciparum isolates from the Thai-Myanmar border. Acta Trop 2011; 120:130-5.
11. Phompradit P, Muhamad P, Wisedpanichkij R, Chaijaroenkul W, Na-Bangchang K. Four years' monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border. Malar J 2014; 13:23.
12. Kwansa-Bentum B, Ayi I, Suzuki T, et al. Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-Type PfATPase6 though sensitive to artesunate in vitro. Malar J 2011; 10:187.
13. Marina Chavchich LG, Peters J, Chen N, Cheng Q, Kyle DE. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob Agents Chemother 2010; 56:2455-64.
14. Dahlstrom S, Ferreira P, Veiga M, et al. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis 2009; 200:1456-64.
15. Veiga MI, Ferreira PE, Jörnhagen L, et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One 2011; 6:e20212.
16. Gupta B, Xu S, Wang Z, et al. Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar. Antimicrob Agents Chemother 2014; 69:2110-7.
17. World Health Organization. Status report on artemisinin resistance-January 2014. Geneva, Switzerland: WHO, 2013.
18. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014; 505:50-5.
19. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. New Engl J Med 2014; 371: 411-23.
20. White N. The parasite clearance curve. Malar J 2011; 10:278.
21. Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010; 201:570-9.
22. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva, Switzerland: WHO, 2009.
23. Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman HA. A genus-And species-specific nested polymerase chain reaction malaria detection assay for epidemiologic studies. Am J Trop Med Hyg 1999; 60:687-92.
24. World Health Organization. Global plan for artemisinin resistance containment (GPARC). Geneva, Switzerland: WHO, 2011.
25. Basco LK. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva, Switzerland: WHO, 2007.
26. World Health Organization. Guideline for treatment of malaria. 2nd ed. Geneva, Switzerland: WHO, 2010.
27. Cox J, Dy Soley L, Bunkea T, et al. Evaluation of community-based systems for the surveillance of day three-positive Plasmodium falciparum cases in western Cambodia. Malar J 2014; 13:282.
28. Dahlström S, Ferreira PE, Veiga MI, Sedighi N. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis 2009; 200:1456-64.
29. Raj D, Mu J, Jiang H, et al. Disruption of a Plasmodium falciparum multidrug resistance-Associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem 2009; 284:7687-96.
30. Li X, Zhang D, Hannink M, Beamer LJ. Crystal structure of the kelch domain of human Keap1. J Biol Chem 2004; 279:54750-8.